2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3863 The TBX21-ZNF683 T-cell axis orchestrates natural control of chronic lymphocytic leukemia

Marwan Kwok, MD, PhD, MRCP, FRCPath, Lingting Shi, PhD2, Angie McGraw3, Connor Johnson, BS4, Johanna M van Vliet, MSc5, Connor Richterich6, Sharanya Chatterjee7, Mohamad Sabbah, MD8, Xingli Yu9, Falak Pabari10, Jeroen Geerligs11, Anne-Marie Hewitt12, Kathrine Moravick13, Abi Vijenthira, MD, MS14, Chip Stewart, PhD15, Stacey M. Fernandes, BS16, Lita Freeman, PhD17, Gerald Marti, MD18, Andy Rawstron, PhD19, Peter Hillmen, PhD, MBBCh20, Helen Marie Parry, MD, PhD21, Guy Pratt22, Shankaranarayana Paneesha, MD23, Tatjana Stankovic, MD, PhD24, Inhye E Ahn, MD25, Elisa ten Hacken, PhD26, Erin Parry, MD, PhD27, Shuqiang Li, PhD28, Kenneth Livak29, Ton Schumacher, PhD30, Adrian Wiestner, MD, PhD31, Paul Moss, PhD32, Jennifer R. Brown, MD, PhD33, Gaddy Getz, PhD34, Jeremy M Simon, PhD35, Elham Azizi36, Catherine J. Wu, MD37
1 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom
2 Columbia University, New York, New York, United States, Columbia University, New York, New York, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States
5 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Netherlands Cancer Institute, Amsterdam, Netherlands
7 Columbia University, New York, New York, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Hôpital Saint-Louis, Paris, France
9 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
10 Columbia University, New York, New York, United States
11 Netherlands Cancer Institute, Amsterdam, Netherlands
12 University of Birmingham, Birmingham, United Kingdom
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Northeastern University, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
15 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 National Institutes of Health, Bethesda, Maryland, United States
18 National Institutes of Health, Bethesda, Maryland, United States
19 St James's University Hospital, Leeds, United Kingdom, University of Leeds, Leeds, United Kingdom
20 St James's University Hospital, Leeds, United Kingdom, University of Leeds, Leeds, United Kingdom
21 Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom
22 Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom
23 Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom
24 University of Birmingham, Birmingham, United Kingdom
25 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
26 Cornell University, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
27 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
28 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
29 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
30 Netherlands Cancer Institute, Amsterdam, Netherlands
31 National Institutes of Health, Bethesda, Maryland, United States
32 Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom
33 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
34 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States
35 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
36 Columbia University, New York, New York, United States, Columbia University, New York, New York, United States
37 Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Spontaneous regression of chronic lymphocytic leukemia (SR-CLL) is characterized by a sustained reduction of ≥50% in CLL burden without treatment, often to clinically undetectable levels. Although rare, this phenomenon is thought to indicate effective host immunity against CLL. We hypothesized that the mechanism underlying SR-CLL involves distinct tumor-intrinsic features coupled with an optimal immune microenvironment that collectively facilitate disease control.

To uncover key determinants of SR-CLL, we interrogated the bone marrow (BM) microenvironment by paired scRNA/TCR-seq and scATAC-seq, analyzing samples from patients with SR-CLL at the time of regression (n=5) and comparing them to biologically matched controls with progressive CLL (P-CLL, n=4) or stable CLL (S-CLL, n=4; defined as <10% change in WBC over ≥10 years). In parallel, longitudinal blood (PB) samples from 25 SR-CLL and 8 P-CLL patients (1-3 samples per patient over a median of 12 years) were characterized by the same single-cell platforms. We isolated immune and CLL cells from both BM and PB, re-pooling them at a 3:1 ratio to generate 1,149,513 scRNA-seq and 229,251 scATAC-seq profiles, including 456,345 and 85,596 T cells, respectively.

Within the T-cell compartment, SR-CLL and S-CLL BM and PB displayed increased GZMB+ ZNF683+ CD8 effector memory T cells (16.9% vs 4.8%, p=0.04) and decreased regulatory T cells (1.5% vs 7.1%, p=0.03) compared to P-CLL across all longitudinal timepoints. These differences manifested in greater in vitro CD8 T-cell reactivity against autologous CLL cells in SR-CLL vs P-CLL (10.6% vs 1.3% IFN-γ+, p=0.002). We further identified a TRA+TRB+ CD4-CD8A- FAS+ stem-cell memory-like T-cell (TSCM) population with pronounced expression of BACH2, TCF7 and ZEB1, but undetectable TOX, immune checkpoint or granzyme expression. Primarily detected in SR-CLL patients across both PB and BM, this population constituted ≥1% of total T cells in 13 of 25 patients, and ≥10% in 8 of 25 patients. Mirroring this T-cell landscape, IFN-α/γ and TNFα pathways were the most differentially upregulated in leukemia cells from SR-CLL patients. Bulk RNA-seq analysis of an expanded cohort confirmed these findings, revealing enrichment of the proinflammatory EC-m4 expression cluster, previously defined in the CLL-Map multi-omic atlas, in SR-CLL vs non-SR-CLL (79% vs 19%; n=38 and n=603, respectively).

We investigated whether the ZNF683+ CD8 cluster originates from the TSCM progenitor pool, and whether it represents a bona fide CLL-reactive population. Longitudinal tracking of shared TCR clonotypes revealed greater T-cell plasticity and more prominent phenotypic transitions in SR-CLL than P-CLL. We observed TSCM transitions to central/effector memory (including ZNF683+) states in 6 of 14 SR-CLL patients, whereas ≥50% of shared clonotypes already displayed the ZNF683+ state at the earliest sampling in 3 of 14 SR-CLL cases. This TSCM-to-ZNF683+ continuum was corroborated by trajectory inference using Decipher, which also revealed clonotypic expansion concomitant with transition to the ZNF683+ state. To identify the phenotype of CLL-reactive T cells, we performed TCR-seq on FACS-sorted IFN-γ+ T cells. Using their CDR3 sequences as barcodes, we mapped these T cells to their native states in our scRNA/TCR-seq dataset, revealing their preferential localization within the ZNF683+ CD8 cluster. As validation, we reconstructed 955 TCRs from CLL-reactive, IFN-γ-secreting T cells identified in 6 SR-CLL patients within our primary screen, with confirmatory testing against autologous CLL underway.

The presence of naturally expanded ZNF683+ T cells in SR-CLL patients motivated us to investigate the epigenetic underpinnings shaping this distinct T-cell landscape. Accordingly, scATAC-seq of ZNF683+ CD8 T cells revealed an enrichment of sequence motifs (q<0.001) and binding sites (p<0.001) for the transcription factor TBX21 in regions with increased chromatin accessibility between SR-CLL and P-CLL, in both BM and PB, across longitudinal timepoints before and after spontaneous regression. Moreover, we identified 2 TBX21-bound loci within 5 kb upstream of the ZNF683 promoter with increased accessibility in SR-CLL (nominal p=0.01). Collectively, our analysis defines a spontaneous regression-associated stem-to-effector T cell program and implicates a TBX21-ZNF683 T-cell regulatory axis central to the natural control of CLL, providing a blueprint for advancing CLL immunotherapy.

Marwan Kwok, MD, PhD, MRCP, FRCPath: No relevant conflicts of interest to declare.